

Open  Access

Research Article

## Development and Validation of Stability indicating RP- HPLC method for Simultaneous Estimation of Sofosbuvir and Ledipasvir in Bulk Tablet Dosage Form

S.D. Mankar\*, S.B. Bhawar, P.R. Dalavi

Department of Quality Assurance Technique, Pravara Rural College of Pharmacy, Pravaranagar, Tal-Rahata, Dist-Ahmednagar, India

### ABSTRACT

The present research work describes a simple, accurate, precise, effective, Stability indicating RP-HPLC method for simultaneous estimation of Sofosbuvir and Ledipasvir in their tablet dosage form. A reverse phase high performance chromatographic method was developed for simultaneous estimation of Sofosbuvir and Ledipasvir their combined dosage. The separation was achieved by Inertsil ODS C18 column (150X4.6mm, 5µm) column, and ACN: 0.1% TFA in the proportion of 30:70 %v/v as mobile phase, at a flow rate of 1 ml/min. Detection was carried out at 245 nm. For RP-HPLC method results of the validation indicate that the method was linear in the range of 100-600µg/ml for Sofosbuvir and 22.5-135µg/ml for Ledipasvir. The % recoveries for Sofosbuvir and Ledipasvir obtained in the accuracy study were 99.92-100.31% and 99.84-100.55% respectively. The LOD for Sofosbuvir and Ledipasvir were found to be 0.395µg/ml and 0.132µg/ml respectively. LOQ for Sofosbuvir and Ledipasvir were found to be 1.197µg/ml and 0.401µg/ml respectively. Force degradation study also done and method is stability indicating. Developed methods were found to be accurate, precise, rapid and stability indicating for simultaneous estimation of Sofosbuvir and Ledipasvir.

**Keywords:** RP-HPLC, Sofosbuvir, Ledipasvir, ACN, TFA.

**Article Info:** Received 07 May 2019; Review Completed 06 June 2019; Accepted 09 June 2019; Available online 15 June 2019



### Cite this article as:

Mankar SD, Bhawar SB, Dalavi PR, Development and Validation of Stability indicating RP- HPLC method for Simultaneous Estimation of Sofosbuvir and Ledipasvir in Bulk Tablet Dosage Form, Journal of Drug Delivery and Therapeutics. 2019; 9(3-s):500-509 <http://dx.doi.org/10.22270/jddt.v9i3-s.2893>

### \*Address for Correspondence:

S.D. Mankar, Department of Quality Assurance Technique, Pravara Rural College of Pharmacy, Pravaranagar, Tal-Rahata, Dist-Ahmednagar, India

### INTRODUCTION

#### 1.1 SOFOSBUVIR

propan-2-yl [(2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxypyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxyphenoxyphosphoryl]amino]propanoate.<sup>[1]</sup> It is indicated for the treatment of chronic HCV genotypes 1, 4, 5, and 6 in adults and also indicated for the treatment of chronic HCV in patients co-infected with HIV. <sup>[2]</sup> Slightly soluble in water pH 1.2-7.7, freely soluble in ethanol and acetone, soluble in 2-propanol and insoluble in heptanes.<sup>[3]</sup>

**Mol. formula:** C<sub>22</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>9</sub>P **Mol. weight:** 529.4525242 gm/mol.

#### Structure:




Figure 1: Chemical structure of Sofosbuvir

**Mechanism of action:** Sofosbuvir is a direct-acting antiviral agent against the hepatitis C virus. The HCV polymerase NS5B protein is an RNA-dependent RNA polymerase (RdRp). It is the essential initiating and catalytic subunit of this replication complex and is critical for the viral replication cycle. There is no human homolog for HCV NS5B RdRp. Sofosbuvir is a monophosphorylated pyrimidine nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203). GS-461203 competes with natural nucleotides for incorporation (by HCV NS5B) into the nascent RNA strand during replication of the viral genome. GS-461203 differs from endogenous pyrimidine nucleotides in that it has been modified at the 2' position with the addition of a methyl and a fluoro functional group. Incorporation of GS-461203 into nascent RNA strongly reduces the efficiency of further RNA elongation by RdRp, resulting in premature termination of RNA synthesis. The stopping of viral replication leads to a rapid decline of HCV viral load and clearing of HCV levels in the body.<sup>[4,5]</sup>

#### 1.2. LEDIPASVIR


The chemical name is methyl [(2S)-1-[(6S)-6-[4-(9,9-

difluoro-7-{2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate [6]. Ledipasvir is practically insoluble <0.1 mg/ml across the pH range of 3.0-7.5 and is slightly soluble below pH 2.3 1.1 mg/ml. The partition coefficient for Ledipasvir is 3.8 and the pKa1 is 4.0 and pKa2 is 5.0.[7]

**Molecular formula:** C<sub>49</sub>H<sub>54</sub>F<sub>2</sub>N<sub>8</sub>O<sub>6</sub>

**Molecular weight:** 888.999866 gm/mole.

**Structure:**



**Figure 2: Chemical structure of Ledipasvir**

#### Mechanism of action:

Ledipasvir inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion. Ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral production. It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV [8,9]

According to the best of our knowledge, only four HPLC methods<sup>[10-13]</sup> have been published, during the preparation of the present work for publishing. The present study aimed to develop a simple, sensitive, short retention time and accurate RP-HPLC method for the simultaneous determination of both sofosbuvir and ledipasvir together in pure and tablet dosage forms with high sensitivity, selectivity that can be used for the routine analysis of production samples.

## 2. MATERIAL AND METHOD

### 2.1. Instruments and Apparatus :

- Ultrasonic Cleaner-5510
- Glass wares – volumetric flask (10, 50 and 100 ml), pipettes beaker (500 ml), measuring cylinder(25, 50, 100 ml) (Borosil)
- What man filter paper no.41
- Thermo separation HPLC (Assemble), UV-200 detector (single wavelength), Rheodyne injector (20 µl).
- 0.45 µm Nylon 66 (Milipore, India)
- Analytical Balance (Swisser)

All instruments and glass wares were calibrated.

### 2.2. Preparation of Solutions

#### • Preparation of the Buffer solution

Diluted 1.0 ml of Trifluoro acetic acid in 1000ml of purified water and mixed.

Filter the resultant solution through 0.45µm Nylon membrane filter.

#### • Preparation of the Mobile phase

Prepared a filtered and degassed mixture of buffer solution and acetonitrile in the ratio of (70:30 %v/v).

### 2.3. Preparation of Standard Solutions

#### ▪ Preparation of Standard Solution of Sofosbuvir

Accurately weighed quantity of Sofosbuvir 200.00 mg was transferred into 100 ml volumetric flask, sonicated to dissolve and diluted up to mark with diluent to give a stock solution 2000µg/ml. An aliquot 5.0 ml of the solution was transferred to 50 ml volumetric flask and diluted to the mark with diluent to obtain a working standard solution 200µg/ml of Sofosbuvir.

#### ▪ Preparation of Standard Solution of Ledipasvir

Accurately weighed quantity of Ledipasvir 45.00 mg was transferred into 100 ml volumetric flask, sonicated to dissolve and diluted up to mark with diluent to give a stock solution 450µg/ml. An aliquot 5.0 ml of the solution was transferred to a 50 ml volumetric flask and diluted to the mark with diluent to obtain a working standard solution 45µg/ml of Ledipasvir.

#### ▪ Preparation of Combined Standard Solution of Sofosbuvir and Ledipasvir:

Accurately weighed Sofosbuvir 200.00 mg and Ledipasvir 45.00 mg were transferred into 100 ml volumetric flask, sonicated to dissolve and diluted up to mark with diluent to give a stock solution 2000µg/ml of Sofosbuvir and 450µg/ml Ledipasvir. Designate it as a combine stock solution

Stock solution 5.0 ml was transferred to 50 ml volumetric flask and diluted up to mark with diluent to obtain working standard solution 200µg/ml of Sofosbuvir and 45µg/ml Ledipasvir.

#### ▪ Preparation of Sample Solution of Sofosbuvir and Ledipasvir

Twenty tablets were weighed and finely powdered. Powdered equivalent to 400 mg Sofosbuvir and 90 mg Ledipasvir was accurately weighed and transferred to 200 ml volumetric flask, and 140 ml of diluent was added and sonicated for 20 min finally volume was made up to the mark with diluent. The solution was filtered through whatmann filter paper (0.45µ). From this solution 5.0 ml was transferred to 50 ml volumetric flask and volume was made up to the mark with diluent to give a solution containing 200µg/ml Sofosbuvir and 45µg/ml Ledipasvir.

### 2.4. Selection of Wavelength for Estimation

Standard solution of Sofosbuvir 40µg/ml and Ledipasvir 9.0µg/ml were prepared using their working standard solution using diluent as a solvent. Each solution was scanned between 200-400 nm using diluent as a blank. The point at which both drug shows absorbance was selected as wavelength for estimation (245nm).




Figure 3: Spectra of standard Sofosbuvir and Ledipasvir for wavelength selection

Table 1: Optimized chromatographic condition

| Parameters               | Condition   |
|--------------------------|---|
| Stationary phase         | Inertsil ODS C18 column (150mm X 4.6 mm, 5 μm particle size)s |
| Mobile Phase             | 0.1% TFA : Acetonitrile (70:30%v/v)                           |
| Pump mode                | Isocratic   |
| Flow rate (ml/min)       | 1.0   |
| Run time (min)           | 7.0   |
| Volume of Injection (μl) | 20  |
| Detection wavelength     | 245   |
| Retention time (min)     | Sofosbuvir : 2.39<br>Ledipasvir : 5.51                        |

Table 2: System suitability parameters for final optimized chromatographic conditions

| Parameters             | Data obtained |            |
|------------------------|---------------|------------|
|                        | Sofosbuvir    | Ledipasvir |
| Retention time (Rt)    | 2.39min       | 5.51 min   |
| Resolution             | 7.22          |            |
| Theoretical plates (N) | 4025          | 8977       |
| Tailing factor (Tr)    | 1.05          | 1.11       |

So, from all the above explained parameters, it was concluded that that the most efficient resolution and peak symmetry for Sofosbuvir and Ledipasvir were achieved with the above chromatographic conditions and with a mobile phase composed of 0.1%TFA :Acetonitrile (70 : 30 %v/v)




Figure 4: Chromatogram of standard showing separated peaks of Sofosbuvir and Ledipasvir

**3. Method Validation**


The described method has been validated for linearity, accuracy, limit of detection, precision, and robustness, as per ICH guidelines.<sup>[14]</sup>

**3.1. Linearity and Range:**

Linear relation was obtained between mean peak area and concentration of the drug in the range of 100-600 µg/ml for Sofosbuvir and 22.5-135 µg/ml for Ledipasvir. The data of the peak areas obtained with the respective concentration in µg/ml are shown in Table 3 and 5 for Sofosbuvir and Ledipasvir respectively. The linearity curves for Sofosbuvir and Ledipasvir are shown in Fig.5 and 6 respectively.

**Table 3: Data of peak areas of Sofosbuvir(100-600µg/ml)**

| Sr. No. | Concentration (µg/ml) | Peak area of Sofosbuvir |
|---------|-----------------------|-------------------------|
| 1       | 100                   | 6018619                 |
| 2       | 200                   | 12053329                |
| 3       | 300                   | 18074368                |
| 4       | 400                   | 24115257                |
| 5       | 500                   | 30130479                |
| 6       | 600                   | 36151273                |




**Fig. 5: Calibration curve for Sofosbuvir**

**Table 4: Data showing regression characteristics of Sofosbuvir**

|                         |                               |
|-------------------------|-------------------------------|
| Regression equation     | $Y = 60267.3169x - 3006.7333$ |
| Regression co-efficient | 1.0000                        |

**Table 5: Data of peak areas of Ledipasvir (22.5-135 µg/ml)**

| Sr. No. | Concentration (µg/ml) | Peak area of Ledipasvir |
|---------|-----------------------|-------------------------|
| 1       | 22.5                  | 806846                  |
| 2       | 45                    | 1618653                 |
| 3       | 67.5                  | 2427643                 |
| 4       | 90                    | 3237175                 |
| 5       | 112.5                 | 4043608                 |
| 6       | 135                   | 4855008                 |



**Fig. 6 : Calibration curve for Ledipasvir**

**Table 6: Data showing regression characteristics of Ledipasvir**

|                         |                             |
|-------------------------|-----------------------------|
| Regression equation     | $Y = 35968.52x - 1031.8667$ |
| Regression co-efficient | 1.0000                      |

### 3.2. Accuracy

Accuracy refers to closeness of the test results obtained by the method to the true value. Accuracy was performed by the standard addition methods. To a fixed amount of the pre-analysed mixture add a 50%, 100% and 150% of the standard solution and % recovery was calculated. The results are shown in Table 7

**Table 7: Recovery data for Sofosbuvir**

| Amount of Sofosbuvir Present ( $\mu\text{g/ml}$ ) | Amount of Std Sofosbuvir Added ( $\mu\text{g/ml}$ ) | Total Amount of Sofosbuvir ( $\mu\text{g/ml}$ ) | Amount Recovered ( $\mu\text{g/ml}$ ) | % Recovery    |
|---|---|---|---------------------------------------|---------------|
| 200   | 300   | 500   | 499.830                               | <b>99.92</b>  |
|   |   |   | 501.982                               |               |
|   |   |   | 496.986                               |               |
| 200   | 200   | 400   | 401.139                               | <b>99.72</b>  |
|   |   |   | 396.993                               |               |
|   |   |   | 398.532                               |               |
| 200   | 100   | 300   | 300.381                               | <b>100.31</b> |
|   |   |   | 300.357                               |               |
|   |   |   | 302.039                               |               |

**Table 8: Recovery data for Ledipasvir**

| Amount of Ledipasvir Present ( $\mu\text{g/ml}$ ) | Amount of Std Ledipasvir Added ( $\mu\text{g/ml}$ ) | Total Amount of Ledipasvir ( $\mu\text{g/ml}$ ) | Amount Recovered ( $\mu\text{g/ml}$ ) | % Recovery    |
|---|---|---|---------------------------------------|---------------|
| 45  | 67.5  | 112.5   | 112.575                               | <b>100.45</b> |
|   |   |   | 113.023                               |               |
|   |   |   | 113.423                               |               |
| 45  | 45  | 90  | 90.652                                | <b>99.84</b>  |
|   |   |   | 89.607                                |               |
|   |   |   | 89.307                                |               |
| 45  | 22.5  | 67.5  | 67.035                                | <b>100.55</b> |
|   |   |   | 68.129                                |               |
|   |   |   | 68.453                                |               |

### 3.3. Precision

#### 3.3.1. Repeatability

It was performed by 100% test concentration level and % RSD was calculated. The data for repeatability for combined solution of Sofosbuvir and Ledipasvir is presented in Table 9

**Table 9: Repeatability of Sofosbuvir and Ledipasvir**

| Sr. No.      | Sofosbuvir (200 $\mu\text{g/ml}$ ) | Ledipasvir (45 $\mu\text{g/ml}$ ). |
|--------------|------------------------------------|------------------------------------|
| 1            | 12363864                           | 1532054                            |
| 2            | 12264518                           | 1528040                            |
| 3            | 12288474                           | 1530889                            |
| 4            | 12289526                           | 1530928                            |
| 5            | 12303266                           | 1532196                            |
| 6            | 12245790                           | 1552151                            |
| <b>Mean</b>  | <b>12292573</b>                    | <b>1534376</b>                     |
| <b>SD</b>    | <b>40493.37</b>                    | <b>8835.02</b>                     |
| <b>% RSD</b> | <b>0.33</b>                        | <b>0.58</b>                        |

### 3.3.2. Interday and Intraday Precision of Sofosbuvir:

The data for Intraday and Interday precision for Sofosbuvir are presented in Table 10 for Intraday Sample solutions containing 200µg/ml of Sofosbuvir and 45µg/ml Ledipasvir

were prepared six times and measured on the same day and % RSD was calculated. For Interday Sample solutions containing 200µg/ml of Sofosbuvir and 45µg/ml Ledipasvir were prepared six times and measured on the different days and % RSD was calculated.

**Table 10: Intraday and Interday precision data for Sofosbuvir**

| Concentration (µg/ml) | Intraday               |       | Interday               |             |
|-----------------------|------------------------|-------|------------------------|-------------|
|                       | Mean % Estimation ± SD | % RSD | Mean % Estimation ± SD | % RSD       |
| 200                   | 100.10 ± 0.5462        | 0.55  | 100.24 ± 0.7162        | <b>0.71</b> |

### 3.3.3. Intraday and Interday Precision of Ledipasvir :

The data for Intraday and Interday precision for Ledipasvir

are presented in Table: 10 The % RSD for Intraday precision was found to be 0.53 for Ledipasvir. The % RSD for Interday precision was found to be 0.67 for Ledipasvir.

**Table 11: Intraday and Interday precision data of Ledipasvir**

| Concentration (µg/ml) | Intraday               |             | Interday               |             |
|-----------------------|------------------------|-------------|------------------------|-------------|
|                       | Mean % Estimation ± SD | % RSD       | Mean % Estimation ± SD | % RSD       |
| 45                    | 100.05 ± 0.5281        | <b>0.53</b> | 100.03 ± 0.6682        | <b>0.67</b> |

### 3.4. Limit of Detection (LOD) and Limit of Quantification (LOQ)

**Table 12: Limit of detection**

| Sofosbuvir   | Ledipasvir   |
|--|--|
| LOD = 3.3 x (SD/Slope)<br>LOD = 3.3 x (7214/60267.3169)<br>LOD = 0.395 µg/ml | LOD = 3.3 x (SD/Slope)<br>LOD = 3.3 x (1443/35968.5168)<br>LOD = 0.132 µg/ml |


**Table 13: Limit of Quantification**

| Sofosbuvir   | Ledipasvir   |
|--|--|
| LOQ = 10 x (SD/Slope)<br>LOQ = 10 x (7214/60267.3169)<br>LOQ = 1.197 µg/ml | LOQ = 10 x (SD/Slope)<br>LOQ = 10 x (1443/35968.5168)<br>LOQ = 0.401 µg/ml |

### 3.5. Specificity

The specificity was determined by the comparison of the chromatograms of:

- Blank (mobile phase) (Fig 7)
- Standard sample solutions of Sofosbuvir and Ledipasvir(Fig.8 and 9 for Sofosbuvir and Ledipasvir respectively),
- Sample solution of Sofosbuvir and Ledipasvir (Fig. 10).



**Fig.7: Chromatogram of Blank (mobile phase)**




Fig. 8: Chromatogram of standard Sofosbuvir




Fig. 9: Chromatogram of standard Ledipasvir




Fig. 10: Chromatogram of sample solution containing Sofosbuvir(200µg/ml) and Ledipasvir (45µg/ml)

3.6. Robustness

Robustness study was performed in following altered chromatographic condition:

Variation in the flow rate ( $\pm 0.2$  mL/min)

Variation in mobile phase composition ( $\pm 2\%$ )

Table 14: Robustness data for  $\pm 0.2$  mL/min variation in Flow rate

| Flow rate  | Peak area |         | Mean $\pm$ SD  |               | % RSD       |             |
|------------|-----------|---------|----------------|---------------|-------------|-------------|
|            | SOFOS     | LEDI    | SOF            | LED           | SOF         | LED         |
| 0.8 mL/min | 14313927  | 1757607 | 14350196 $\pm$ | 1757224 $\pm$ | <b>0.36</b> | <b>0.03</b> |
|            | 14386465  | 1756842 | 51292.1117     | 540.9367      |             |             |
| 1.2 mL/min | 11094624  | 1380696 | 11096462 $\pm$ | 1380890 $\pm$ | <b>0.02</b> | <b>0.02</b> |
|            | 11098300  | 1381085 | 2599.3245      | 275.0645      |             |             |

Table 15: Robustness data for  $\pm 2\%$  variation in mobile phase

| Mobile phase | Peak area |         | Mean $\pm$ SD  |               | % RSD       |             |
|--------------|-----------|---------|----------------|---------------|-------------|-------------|
|              | SOFOS     | LEDI    | SOF            | LED           | SOF         | LED         |
| 72:28        | 12441394  | 1540933 | 12450838 $\pm$ | 1542977 $\pm$ | <b>0.11</b> | <b>0.19</b> |
|              | 12460281  | 1545020 | 13355.1258     | 2889.9454     |             |             |
| 68:32        | 12371514  | 1547725 | 12371612 $\pm$ | 1547848 $\pm$ | <b>0.00</b> | <b>0.01</b> |
|              | 12371709  | 1547971 | 137.8858       | 173.9483      |             |             |

#### 4. Assay Formulation analysis

**Table 16: Estimation of Sofosbuvir and Ledipasvir in their Pharmaceutical Dosage Form (Tablet)**

| Labelled Value (mg) | Amt of Sofosbuvir found (mg) | % Assay       | Labelled Value (mg) | Amt of Ledipasvir found (mg) | % Assay       |
|---------------------|------------------------------|---------------|---------------------|------------------------------|---------------|
| 400                 | 402.16                       | 100.54        | 90                  | 90.20                        | 100.23        |
|                     | 398.92                       | 99.73         |                     | 89.66                        | 99.62         |
|                     | 402.05                       | 100.51        |                     | 90.00                        | 100.01        |
|                     | 403.38                       | 100.84        |                     | 90.26                        | 100.29        |
|                     | 401.36                       | 100.34        |                     | 90.41                        | 100.46        |
|                     | 402.93                       | 100.73        |                     | 90.00                        | 100.00        |
| <b>Mean</b>         | <b>401.80</b>                | <b>100.45</b> | <b>Mean</b>         | <b>90.09</b>                 | <b>100.10</b> |
| <b>SD</b>           | <b>1.5791</b>                | <b>0.3948</b> | <b>SD</b>           | <b>0.2625</b>                | <b>0.2917</b> |
| <b>% RSD</b>        | <b>0.39</b>                  | <b>0.39</b>   | <b>% RSD</b>        | <b>0.29</b>                  | <b>0.29</b>   |

#### 5. Force degradation studies

##### 5.1. Preparation of sample stock solution

Accurately weighed Sofosbuvir (200.00 mg) and Ledipasvir (45.00 mg) were transferred into 100 ml volumetric flask, sonicated to dissolve and diluted up to mark with diluent to give a stock solution (2000µg/ml) of Sofosbuvir and (450µg/ml) Ledipasvir. Designate it as a combine stock solution. Stock solution (5.0 ml) was transferred to 50 ml volumetric flask and diluted up to mark with diluent to obtain working standard solution (200µg/ml) of Sofosbuvir and (45µg/ml) Ledipasvir.

##### 5.2. Acid degradation study (5NHCL)

From the test stock solution 1ml was taken in 10 ml volumetric flask, add 1ml of 5N HCL and heated at 60° for 30 min on a water bath. The flask was removed from the water bath and allows to cool at room temperature. Add 1ml of 5N NaoH to neutralize the solution and diluted to volume with diluents and mixed. 10µl solution were injected in to the system and the chromatograms were recorded to assess the stability of sample.

##### 5.3. Alkali degradation studies (5N NaoH)

From the test stock solution 1ml was taken in 10ml volumetric flask, add 1ml of 5N NaoH and heated at 70°c for 1h on a water bath. The flask was removed from the water bath and allowed to cool at room temperature. Add 1ml of 5 N HCL to neutralize the solution and diluted to volume with diluents and mixed. 10µl solution were injected in to the system and chromatograms were recorded to asses the stability of sample.

##### 5.4. peroxide (Oxidation) degradation studies (30%v/v of H2O2)

From the test stock solution 1ml Was taken in 10ml volumetric flask add 1ml of 30% H2O2 and heated at 70° c for 1hour on a water bath. The flask was removed from the water bath and allowed to cool at room temperature and diluted to volume with diluents and mixed. 10µl solutions were injected in to the system and the chromatograms were recorded to access the stability of sample.

##### 5.5. Thermal degradation studies (105°c/ 48hr)

For the thermal degradation 200mg Sofosbuvir and 45mg lLedipasvir drug samples were weighed accurately and transfer to petridish heat the sample in oven for 48hr at 105°c and transfer the sample into a 100ml volumetric flask dissolve and dilute to volume with diluents. Filter the solution using 0.45µ Nylon filter. Transfer 5ml of above stock solution to 50ml volumetric flask and make up the volume with diluents to get the concentration of (200µg/ml)

of Sofosbuvir and (45µg/ml) Ledipasvir. 10 µl solutions was injected into the system and the chromatogram recorded to access the stability of sample.

##### 5.6. Photolytic degradation (2600lux for 24hr)

For the thermal degradation 200mg Sofosbuvir and 45mg lLedipasvir drug samples were weighed accurately and transfer to petridish. The sample was exposed to UV light in a photolytic chamber at 1.2 million lux hours for 24h and transfer the sample into a 100ml volumetric flask dissolve and dilute to volume with diluents. Filter the solution using 0.45µ Nylon filter. Transfer 5ml of above stock solution to 50ml volumetric flask and make up the volume with diluents to get the concentration of (200µg/ml) of Sofosbuvir and (45µg/ml) Ledipasvir. . 10µl solutions was injected into the system and the chromatogram recorded to access the stability of sample.

#### 6. RESULT AND DISCUSSION

##### 6.1. Optimized chromatographic conditions

The optimized chromatographic conditions fig3. The best peak shape and maximum separation was achieved with mobile phase ACN : 0.1% TFA in the proportion of 30:70 %v/v, peak symmetry and reproducibility obtained on inetsil ODS C18 column (150X4.6mm, 5µm), optimum Wave length To detecting analyte was found to be 245 nm , a flow rate of 1ml/min yield optimum separation and peak symmetry. Chromatogram of Sofosbuvir and Ledipasvir fig 4 and optimized chromatographic condition is shown in table 1.

##### 6.2. Linearity

Linear relation was obtained between mean peak area and concentration of the drug in the range of 100-600 µg/ml for Sofosbuvir and 22.5-135 µg/ml for Ledipasvir. Shown in the fig 5 and 6.

##### 6.3. Accuracy

The percentage recovery for Sofosbuvir were 99.72-100.31% and for Ledipasvir 99.84-100.55%.shown in the Table 6 and 7.

##### 6.4. Precision

###### 6.4.1 Repeatability

The data for repeatability for combined solution of Sofosbuvir and Ledipasvir is presented in Table: 8 and % RSD was found to be 0.33 for Sofosbuvir and 0.58for Ledipasvir.

**6.4.2 Intraday and interday precision**

The data for Intraday and Interday precision for Sofosbuvir are presented in Table: 9. The % RSD for Intraday precision was found to be 0.55 for Sofosbuvir. The % RSD for Interday precision was found to be 0.71 for Sofosbuvir.

The data for Intraday and Interday precision for Ledipasvir are presented in Table: 10. The % RSD for Intraday precision was found to be 0.53 for Ledipasvir. The % RSD for Interday precision was found to be 0.67 for Ledipasvir.

**6.5. LOD and LOQ**

The LOD for Sofosbuvir and Ledipasvir were found to be 0.395µg/ml and 0.132µg/ml respectively, shown in table no 11.

LOQ for Sofosbuvir and Ledipasvir were found to be 1.197µg/ml and 0.401µg/ml respectively, shown in table 12.

**6.6. Specificity**

The specificity of the method was evaluated with regard to interference due to presence of any othe excipient. The figure

show that the selected drugs were clearly separated. Fig 7 and 10 show that the chromatogram of blank , standard. solution. There were no interfering peak at retention time of Sofosbuvir and Ledipasvir.

**6.7. Robustness**


Result of the robustness Table 13 & 14. The elution order and resolution for all components were not significantly affected. RSD of peak area were found to be well within the limit of 2.0%.

**6.8. Degradation study**

All the stability results were shown in table 16 and fig 11 (a-e)

Table 17: stability results

| Stress Condition | Sofosbuvir    | Ledipasvir    |
|------------------|---------------|---------------|
|                  | % Degradation | % Degradation |
| Acid             | 0.44          | 1.18          |
| Basic            | 0.02          | 0.05          |
| Oxidizing        | 0.41          | 1.73          |
| Thermal          | 0.04          | 0.05          |
| Photolysis       | 0.01          | 0.07          |



**Fig 11:** (a) Acid degradation (b) alkali degradation (c) peroxide degradation (d) thermal degradation (e) photodegradation

## 7. CONCLUSION

A simple, fast, accurate and precise stability- indicating HPLC analytical method has been developed and validated for the Quantitative analysis of Sofosbuvir and Ledipasvir in combined tablet dosage forms. The result of stress testing undertake according to the ICH guidelines reveal that the method is specific and stability indicating. The proposed method has the ability to separate these drugs from their degradation products in tablet dosage forms and hence can be applied to the analysis of routine quality control samples obtained from stability studies.

## REFERENCES

1. Sofosbuvir Drug profile, January 2014, <http://www.drugbank.ca/drugs/DB08934>
2. Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C. Gilead Sciences, 2014.
3. Jeffery GH, Bassett J, Mandham J, Denny RC. Vogel's. Text Book of Quantitative Chemical Analysis. 5th Ed. Longman Scientific and Technical Publication, UK; 1994, 3-4.
4. Compound Summary for CID 45375808 "National Center for Biotechnology Information" PubChem Compound Database; CID=45375808, <https://pubchem.ncbi.nlm.nih.gov/compound/Sofosbuvir#section=Top>
5. Vikas PM, Satyanarayana T, Kumar DV, Mounika E, Latha MS, Anusha R, Sathish Y, Development and validation of new RP-HPLC method for the determination of Sofosbuvir in pure form, World Journal of Pharmacy and Pharmaceutical Science. 2016, 5(5):775-781.
6. Ledipasvir Drug profile, January 2014 <http://www.drugbank.ca/drugs/DB09027>
7. Devilal J, Durgaprasad B, Pal N, Rao AS, New method development and validation for the determination of Ledipasvir in bulk drug form by using reverse phase HPLC technique, World Journal of Pharmacy and Pharmaceutical Science. 2016, 5(8): 1312-1321.
8. Compound Summary for CID 67505836 "National Center for Biotechnology Information" PubChem Compound Database; CID=67505836, <https://pubchem.ncbi.nlm.nih.gov/compound/67505836#section=Top>
9. Vikas PM, Satyanarayana T, Kumar DV, Mounika E, Latha MS, Anusha R, Sathish Y, Development and validation of new RP-HPLC method for the determination of Sofosbuvir in pure form, World Journal of Pharmacy and Pharmaceutical Science. 2016, 5(5): 775-781.
10. Nagaraju T, Vardhan SVM, Kumar DR, Ramachandran D, A New RP-HPLC Method for the Simultaneous Assay of SOFOSBUVIR and LEDIPASVIR in Combined Dosage Form, Int. J. of Chem Tech Research. 2017, 10(7): 761-768..
11. Mastanamma SK, Chandini SK, Reehana SK, Saidulu P, Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form, Future Journal of Pharmaceutical Sciences, 2017, 4(2):116-123.
12. Rote AP, Alhat J, Kulkarni A, Development and validation of RPHPLC method for the simultaneous estimation of Ledipasvir and Sofosbuvir in bulk and pharmaceutical dosage form, International Journal of pharmaceutical sciences and drug research. 2017; 9(6):291-298.
13. Rao BS, Reddy MV, Rao S, "Simultaneous analysis of Sofosbuvir and Ledipasvir in bulk and tablet dosage Form by RPHPLC method, Global journal of research analysis. 2017, 6 (4):505-509.
14. International Conference on Harmonization, ICH Guidelines, Validation of analytical procedures technical requirements for registration of pharmaceuticals for human use, Text and Methodology Q 2 (R1), International Conference on Harmonization, Geneva, Switzerland, November 2005.

